PTK2B and Miyoshi myopathy: Previous studies have shown that deferasirox (DFX) could inhibit the proliferation of MM cells, reduce intracellular ROS, and inhibit the expressions of proline-rich tyrosine kinase 2 (Pyk2) and the downstream Wnt/β-catenin signal pathway [45].